Nab-paclitaxel plus bevacizumab for patients with previously treated, metastatic neuroendocrine carcinomas (NEC) – A multicenter, open-label, phase II trial

#3645

Introduction: No standard therapies beyond first line are established for advanced NECs. Most NECs are hyper vascular, and the efficacy of paclitaxel-based combination regimens in the treatment of multiple digestive cancers has been reported.

Aim(s): We conducted a multicenter, open-label, phase II trial evaluating the efficacy and safety of nab-paclitaxel (PTX) plus bevacizumab (bev) in metastatic NECs after one or more lines of therapy.

Materials and methods: Patients with metastatic NECs, and progression on previous therapies were included to receive 150mg/m2 nab-PTX plus 5mg/kg Bev through intravenous infusion once every two weeks until confirmed disease progression or treatment intolerance. The primary end point was OS. Secondary end points included ORR, PFS, DOR, and safety. ClinicalTrials.gov: NCT04705519.

Conference:

Presenting Author:

Authors: Zhang P, Li S, Li J, Lin S, Ming L,

Keywords: NEC, nab-paclitaxel, bevacizumab,